Visit
As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…
Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!
A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple…
Check out our top picks from ESMO 2021!
VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!
VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!
Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and metastatic growth is associated with increased comorbidities. To put the…
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates
Keep up to date with all the latest news with our monthly newsletter